Theravance Biopharma (TBPH) Net Margin (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Net Margin of 28.08% for Q1 2026, up 6016.0% year-over-year from 0.46% in Q1 2025, and down 144.98% quarter-over-quarter from 62.43% in Q4 2025.
Theravance Biopharma (TBPH) Net Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Net Margin for 14 consecutive years, with 28.08% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 6016.0% year-over-year to 28.08%; the TTM figure through Mar 2026 stood at 74.81% (up 16419.0% YoY), while the FY2025 annual figure was 934.52%, up 102215.0% from the prior year.
- Net Margin eased to 28.08% in Q1 2026 per TBPH's latest filing, from 62.43% in the prior quarter.
- Across five years, Net Margin topped out at 7445.92% in Q3 2022 and bottomed at 208.2% in Q1 2023.
- Historically, Net Margin has averaged 421.58% across 5 years, with a median of 30.19% in 2023.
- Annual changes were most pronounced in 2022 — Net Margin jumped 728977 bps — and 2023, when it plunged 750295 bps.
- Theravance Biopharma's Net Margin stood at 26.58% in 2022, then tumbled by 214 bps to 30.19% in 2023, then sank by 174 bps to 82.79% in 2024, then surged by 175 bps to 62.43% in 2025, then sank by 145 bps to 28.08% in 2026.
- Business Quant data shows TBPH's Net Margin at 28.08% in Q1 2026, 62.43% in Q4 2025, and 18.08% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -28.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.45% |
| Mar 31, 2026 | -28.08% |
| Dec 31, 2025 | 62.43% |
| Sep 30, 2025 | 18.08% |
| Jun 30, 2025 | 209.33% |
| Mar 31, 2025 | -88.24% |
| Dec 31, 2024 | -82.79% |
| Sep 30, 2024 | -75.28% |
| Jun 30, 2024 | -115.94% |
| Mar 31, 2024 | -80.42% |
| Dec 31, 2023 | -30.19% |
| Sep 30, 2023 | -57.03% |
| Jun 30, 2023 | -113.79% |
| Mar 31, 2023 | -208.20% |
| Dec 31, 2022 | 26.58% |
| Sep 30, 2022 | 7,445.92% |
| Jun 30, 2022 | 166.33% |
| Mar 31, 2022 | 118.16% |
| Dec 31, 2021 | 172.49% |
| Sep 30, 2021 | 156.15% |